Auditor Expresses Substantial Doubt on Going Concern; Nasdaq Delisting Warning Issued Amid Worsening Financials
POM sits 86% above its 52-week low of $0.065.
Summary
POMDOCTOR Ltd faces severe financial distress, including a going concern warning from its auditor, a Nasdaq delisting notice, and worsening losses, despite a recent IPO.
Key Events · Corporate Governance and Compliance · POM
-
Auditor Expresses Going Concern Doubt
The independent auditor, HYYH CPA. LLC, has included an explanatory paragraph in the financial statements expressing "substantial doubt about our ability to continue as a going concern" for the fiscal year ended December 31, 2025.
-
Nasdaq Delisting Warning Received
The company received a notification on January 29, 2026, for non-compliance with Nasdaq's minimum bid price rule, with a deadline of July 28, 2026, to regain compliance. The current stock price is significantly below the $1.00 threshold.
-
Significant Financial Deterioration
Net loss widened to US$18.7 million in 2025 from US$5.3 million in 2024, and negative operating cash flow increased to US$21.2 million from US$2.3 million. Total liabilities of US$84.2 million far exceed total assets of US$15.38 million.
-
Critical Liquidity Shortfall
As of December 31, 2025, cash and cash equivalents of US$1.4 million are insufficient to cover current liabilities of US$31.2 million, indicating a severe liquidity crisis.
Analysis · POM · Trade & Services
POMDOCTOR Ltd's annual report reveals a critical financial situation, with its auditor explicitly stating "substantial doubt about our ability to continue as a going concern." The company reported a significantly increased net loss of US$18.7 million and negative operating cash flow of US$21.2 million for the year ended December 31, 2025. Its cash balance of US$1.4 million is insufficient to cover current liabilities of US$31.2 million. Furthermore, the company received a Nasdaq delisting warning on January 29, 2026, for failing to meet the minimum bid price requirement, with a compliance deadline of July 28, 2026. The report also discloses three material weaknesses in internal control over financial reporting, indicating significant risks in financial oversight. Despite raising US$20.0 million in net proceeds from its IPO in October 2025, the company's financial health has deteriorated, highlighting severe liquidity and operational challenges.
At the time of this filing, POM was trading at $0.12 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $0.06 to $6.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.